This study examined the relationship between lifestyles (diet, sleep, and physical activity) and glucose responses at a personal level. 36 healthy adults in the Bay Area were monitored for their lifestyles and glucose levels using wearables and continuous glucose monitoring ( NCT03919877 ). Gold-standard metabolic tests were conducted to phenotype metabolic characteristics. Through the lifestyle data (2,307 meals, 1,809 nights, and 2,447 days) and 231,206 CGM readings from metabolically-phenotyped individuals with normoglycemia or prediabetes, we found: 1) eating timing was associated with hyperglycemia, muscle insulin resistance (IR), and incretin dysfunction, whereas nutrient intakes were not; 2) timing of increased activity in muscle IS and IR participants was associated with differential benefits of glucose control; 3) Integrated ML models using lifestyle factors predicted distinct metabolic characteristics (muscle, adipose IR or incretin dysfunction). Our data indicate the differential impact of lifestyles on glucose regulation among individuals with different metabolic phenotypes, highlighting the value of personalized lifestyle modifications.
14 April 2026 in Journal of Diabetes Science and Technology
The classification of diabetes and prediabetes by static glucose thresholds obscures the pathophysiological dysglycemia heterogeneity, primarily driven by insulin resistance (IR), β-cell dysfunction, and incretin deficiency. This review demonstrates that continuous glucose monitoring (CGM) and wearable technologies enable a paradigm shift toward non-invasive, dynamic metabolic phenotyping. We show evidence that machine learning models can leverage high-resolution glucose data from at-home, CGM-enabled oral glucose tolerance tests to accurately predict gold-standard measures of muscle IR and β-cell function. This personalized characterization extends to real-world nutrition, where an individual’s unique postprandial glycemic response (PPGR) to standardized meals, such as the relative glucose spike to potatoes versus grapes, could serve as a biomarker for their metabolic subtype. Moreover, integrating wearable data reveals that habitual diet, sleep, and physical activity patterns, particularly their timing, are uniquely associated with specific metabolic dysfunctions, informing precision lifestyle interventions. The efficacy of dietary mitigators in attenuating PPGR is also shown to be phenotype-dependent. Collectively, this evidence demonstrates that CGM can deconstruct the complexity of early dysglycemia into distinct, actionable subphenotypes. This approach moves beyond simple glycemic control, paving the way for targeted nutritional, behavioral, and pharmacological strategies tailored to an individual’s core metabolic defects, thereby paving the way for a new era of precision diabetes prevention.
Chronic systolic heart failure (HF) is a prevalent and morbid disease with marked variability in its progression and response to therapies. The gut microbiome may play a role in pathophysiology and progression of chronic HF, but clinical studies investigating relationships between the two are lacking. We analyzed the gut microbiome in a cohort of adults with chronic systolic HF caused by non-ischemic cardiomyopathy ( n =59) using multi-omics profiling and, in some cases, longitudinal sampling. We identified microbiome differences compared to healthy subjects ( n =50) and associated these differences with host metabolites, inflammatory markers and physiology. We found depletion of the anti-inflammatory probiotic Bifidobacterium and the associated short chain fatty acid producing and formaldehyde detoxifying pathways in the chronic HF cohort. We also discovered HF-specific microbiome-host immunome interactions. In addition to identifying several taxa and microbial pathways broadly associated with HF disease severity, we found significant links between Bifidobacterium and clinical HF improvement over time. Gut microbiome-host multi-omic data integration revealed a close association between Bifidobacterium and circulating metabolites previously implicated in cardiovascular physiology (e.g., malonic acid), thus pointing to potential mechanisms through which Bifidobacterium may affect chronic HF physiology. Our results suggest that Bifidobacterium may serve as a biomarker for chronic HF trajectory as well as suggest potential novel therapeutic interventions strategies.